6.98 USD
↗ 0.02 (0.29%)PRE MARKET (AS OF 07:31 PM EDT)
Kyverna Therapeutics, Inc. Common Stock
KYTXNASDAQ • USD
Market: OPEN
Kyverna Therapeutics, Inc. Common Stock (KYTX) trades at $6.98 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest KYTX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 15, 2026.
Open?$7.34
High?$7.51
Low?$6.88
Prev. Close?$6.96
Volume?1.0M
Avg. Volume?714.9K
VWAP?$7.00
Rel. Volume?1.40x
Bid / Ask
Bid?$5.93 × 100
Ask?$7.91 × 100
Spread?$1.98
Midpoint?$6.92
Valuation & Ratios
Market Cap?430.4M
Shares Out?61.8M
Float?36.8M
Float %?60.5%
P/E Ratio?N/A
P/B Ratio?2.60
EPS?-$2.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Themes
Employees
149
Market Cap
457.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2024-02-08
Address
5980 HORTON STREET
EMERYVILLE, CA
Phone: (510) 925-2492
EMERYVILLE, CA
Phone: (510) 925-2492
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?3
Momentum?77
Short Sent.?39
Piotroski F-Score?0/9Weak
Altman Z-Score?0.17Distress
Confidence?50%Low
Short InterestSqueeze Risk
Short % of Float?22.99%Squeeze Risk
Short Interest?8.5M
Days to Cover?12.4
Free Float36.8M
Avg Daily Volume684.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?9.06Strong
Quick Ratio?9.06Strong
Cash Ratio?1.39Strong
Debt/Equity?0.15Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.60CHEAP▾
Peers100
S&P62
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-92.2%WEAK▾
S&P3
ROA?-69.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-159045000
Enterprise Value?$423.6M
Fundamentals ratios updated end of day